A human monoclonal antibody against small envelope protein of hepatitis B virus with potent neutralization effect.

Abstract:

:Hepatitis B virus (HBV) produces large (L), middle (M), and small (S) envelope proteins, alternatively referred to as hepatitis B surface antigen (HBsAg). Currently, yeast-derived S protein serves as the preventive vaccine, while hepatitis B immune globulin (HBIG) concentrated from pooled plasma of vaccine recipients is employed for post-exposure prophylaxis. However, only a small proportion of the antibodies in HBIG are HBV specific. In the present study, a human monoclonal anti-S antibody (G12) was developed, produced under GLP conditions, and subjected to a panel of functional assays. In vitro results demonstrated high affinity of G12 for the S protein (KD = 7.56 nM). It reacted with envelope proteins of all 7 HBV genotypes tested (A-F, H) by immunofluorescent staining, and more than 97% of HBsAg-positive patient serum samples by enzyme-linked immunosorbent assay. G12 recognized a conformational epitope, although the exact sequence remains unknown. Strikingly, G12 was at least 1,000-fold more potent than HBIG in neutralizing HBV infectivity in both HepaRG cell line and HepG2 cells reconstituted with the HBV receptor. In a transgenic mouse model of HBV persistence, a single peritoneal injection of G12 markedly diminished serum HBsAg titers in all 7 mice, which was sustained for the observation period of 144 d in mice with low pre-treatment levels. While the therapeutic potential of G12 warrants further investigation using a large number of animals, G12 is a potent neutralizing human monoclonal antibody and a promising candidate to replace or supplement HBIG in the prevention of HBV infection.

journal_name

MAbs

journal_title

mAbs

authors

Wang W,Sun L,Li T,Ma Y,Li J,Liu Y,Li M,Wang L,Li C,Xie Y,Wen Y,Liang M,Chen L,Tong S

doi

10.1080/19420862.2015.1134409

subject

Has Abstract

pub_date

2016-01-01 00:00:00

pages

468-77

issue

3

eissn

1942-0862

issn

1942-0870

journal_volume

8

pub_type

杂志文章

相关文献

mAbs文献大全
  • Ultrafast and high-throughput N-glycan analysis for monoclonal antibodies.

    abstract::Glycosylation is a critical attribute for development and manufacturing of therapeutic monoclonal antibodies (mAbs) in the pharmaceutical industry. Conventional antibody glycan analysis is usually achieved by the 2-aminobenzamide (2-AB) hydrophilic interaction liquid chromatography (HILIC) method following the release...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2016.1156828

    authors: Yang X,Kim SM,Ruzanski R,Chen Y,Moses S,Ling WL,Li X,Wang SC,Li H,Ambrogelly A,Richardson D,Shameem M

    更新日期:2016-05-01 00:00:00

  • Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.

    abstract::An immunotoxin (IT) constructed with RFB4, a murine anti-CD22 monoclonal antibody, and the "deglycosylated" A chain of ricin has shown activity at safe doses in patients with non-Hodgkin lymphoma and in children with acute lymphoblastic leukemia. The dose limiting toxicity is vascular leak syndrome (VLS), which appear...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.4.1.18348

    authors: Liu XY,Pop LM,Schindler J,Vitetta ES

    更新日期:2012-01-01 00:00:00

  • Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use.

    abstract::Ch-mAb7F9, a human-mouse chimeric monoclonal antibody (mAb) designed to bind (+)-methamphetamine (METH) with high affinity and specificity, was produced as a treatment medication for METH abuse. In these studies, we present the preclinical characterization that provided predictive evidence that ch-mAb7F9 may be safe a...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.27620

    authors: Stevens MW,Tawney RL,West CM,Kight AD,Henry RL,Owens SM,Gentry WB

    更新日期:2014-03-01 00:00:00

  • Thermodynamic and structural characterization of an antibody gel.

    abstract::Although extensively studied, protein-protein interactions remain highly elusive and are of increasing interest in drug development. We show the assembly of a monoclonal antibody, using multivalent carboxylate ions, into highly-ordered structures. While the presence and function of similar structures in vivo are not k...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.23183

    authors: Esue O,Xie AX,Kamerzell TJ,Patapoff TW

    更新日期:2013-03-01 00:00:00

  • Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules.

    abstract::Multivalent mono- or bispecific antibodies are of increasing interest for therapeutic applications, such as efficient receptor clustering and activation, or dual targeting approaches. Here, we present a novel platform for the generation of Ig-like molecules, designated diabody-Ig (Db-Ig). The antigen-binding site of D...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2019.1603024

    authors: Seifert O,Rau A,Beha N,Richter F,Kontermann RE

    更新日期:2019-07-01 00:00:00

  • Differences in N-glycan structures found on recombinant IgA1 and IgA2 produced in murine myeloma and CHO cell lines.

    abstract::The development and production of recombinant monoclonal antibodies is well established. Although most of these are IgGs, there is also great interest in producing recombinant IgAs since this isotype plays a critical role in providing immunologic protection at mucosal surfaces. The choice of expression system for prod...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.2.3.11802

    authors: Yoo EM,Yu LJ,Wims LA,Goldberg D,Morrison SL

    更新日期:2010-05-01 00:00:00

  • Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.

    abstract::Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or TRAIL-receptor agonistic monoclonal antibodies promote apoptosis in most cancer cells, and the differential expression of TRAIL-R2 between tumor and normal tissues allows its exploitation as a tumor-associated antigen. The use of thes...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1494105

    authors: Satta A,Mezzanzanica D,Caroli F,Frigerio B,Di Nicola M,Kontermann RE,Iacovelli F,Desideri A,Anichini A,Canevari S,Gianni AM,Figini M

    更新日期:2018-10-01 00:00:00

  • Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life.

    abstract::The neonatal Fc receptor (FcRn) promotes antibody recycling through rescue from normal lysosomal degradation. The binding interaction is pH-dependent with high affinity at low pH, but not under physiological pH conditions. Here, we combined rational design and saturation mutagenesis to generate novel antibody variants...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2019.1633883

    authors: Mackness BC,Jaworski JA,Boudanova E,Park A,Valente D,Mauriac C,Pasquier O,Schmidt T,Kabiri M,Kandira A,Radošević K,Qiu H

    更新日期:2019-10-01 00:00:00

  • Clinical considerations for the development of biosimilars in oncology.

    abstract::Despite availability of biologic therapies, limited patient access to many of the most-effective cancer treatments affects overall health outcomes. To address this issue, many governments have enacted legislation for the approval of biosimilars. The term "biosimilar" refers to a biologic product that is developed to b...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.1080/19420862.2015.1008346

    authors: Socinski MA,Curigliano G,Jacobs I,Gumbiner B,MacDonald J,Thomas D

    更新日期:2015-01-01 00:00:00

  • Guardians at the gate: patent protection for therapeutic monoclonal antibodies--part 1.

    abstract::Patents provide one of the few protections companies can avail themselves of to help protect their therapeutic monoclonal antibody products. Just as the therapeutic monoclonal antibody field is constantly evolving, so too is the legal environment surrounding these inventions. In a series of articles, the general state...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.1.4.8860

    authors: McCabe KW

    更新日期:2009-07-01 00:00:00

  • A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA.

    abstract::Monomeric IgA has been proposed as an alternative antibody format for cancer therapy. Here, we present our studies on the production, purification and functional evaluation of anti-HER2 IgA antibodies as anti-cancer agents in comparison to the anti-HER2 IgG1 trastuzumab. MALDI-TOF MS analysis showed profound differenc...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1102812

    authors: Rouwendal GJ,van der Lee MM,Meyer S,Reiding KR,Schouten J,de Roo G,Egging DF,Leusen JH,Boross P,Wuhrer M,Verheijden GF,Dokter WH,Timmers M,Ubink R

    更新日期:2016-01-01 00:00:00

  • Engineered CH2 domains (nanoantibodies).

    abstract::Currently, almost all FDA approved therapeutic antibodies (except ReoPro, Lucentis and Cimzia which are Fabs), and the vast majority of those in clinical trials are full-size antibodies mostly in IgG1 format of about 150 kDa size. A fundamental problem for such large molecules is their poor penetration into tissues (e...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.4161/mabs.1.1.7480

    authors: Dimitrov DS

    更新日期:2009-01-01 00:00:00

  • The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.

    abstract::Accurate measurement and functional characterization of antibody Fc domain N-linked glycans is critical to successful biosimilar development. Here, we describe the application of methods to accurately quantify and characterize the N-linked glycans of 2 IgG1 biosimilars with effector function activity, and show the pot...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1016692

    authors: Brady LJ,Velayudhan J,Visone DB,Daugherty KC,Bartron JL,Coon M,Cornwall C,Hinckley PJ,Connell-Crowley L

    更新日期:2015-01-01 00:00:00

  • Computational tool for the early screening of monoclonal antibodies for their viscosities.

    abstract::Highly concentrated antibody solutions often exhibit high viscosities, which present a number of challenges for antibody-drug development, manufacturing and administration. The antibody sequence is a key determinant for high viscosity of highly concentrated solutions; therefore, a sequence- or structure-based tool tha...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1099773

    authors: Agrawal NJ,Helk B,Kumar S,Mody N,Sathish HA,Samra HS,Buck PM,Li L,Trout BL

    更新日期:2016-01-01 00:00:00

  • Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor.

    abstract::The neonatal Fc receptor (FcRn) plays an important and well-known role in antibody recycling in endothelial and hematopoietic cells and thus it influences the systemic pharmacokinetics (PK) of immunoglobulin G (IgG). However, considerably less is known about FcRn's role in the metabolism of IgG within individual tissu...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.28254

    authors: Yip V,Palma E,Tesar DB,Mundo EE,Bumbaca D,Torres EK,Reyes NA,Shen BQ,Fielder PJ,Prabhu S,Khawli LA,Boswell CA

    更新日期:2014-05-01 00:00:00

  • Effective binding to protein antigens by antibodies from antibody libraries designed with enhanced protein recognition propensities.

    abstract::Antibodies provide immune protection by recognizing antigens of diverse chemical properties, but elucidating the amino acid sequence-function relationships underlying the specificity and affinity of antibody-antigen interactions remains challenging. We designed and constructed phage-displayed synthetic antibody librar...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1550320

    authors: Jian JW,Chen HS,Chiu YK,Peng HP,Tung CP,Chen IC,Yu CM,Tsou YL,Kuo WY,Hsu HJ,Yang AS

    更新日期:2019-02-01 00:00:00

  • Pharmacokinetic properties of IgG and various Fc fusion proteins in mice.

    abstract::Fusion to an IgG Fc region is an established strategy to extend the half-life of therapeutic proteins. Most Fc fusion proteins, however, do not achieve the long half-life of IgGs. Based on findings that scFv-Fc fusion proteins exhibit a shorter half-life than the corresponding IgG molecules, we performed a comparative...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1113360

    authors: Unverdorben F,Richter F,Hutt M,Seifert O,Malinge P,Fischer N,Kontermann RE

    更新日期:2016-01-01 00:00:00

  • Characterization of monoclonal antibody's binding kinetics using oblique-incidence reflectivity difference approach.

    abstract::Monoclonal antibodies (mAbs) against human proteins are the primary protein capture reagents for basic research, diagnosis, and molecular therapeutics. The 2 most important attributes of mAbs used in all of these applications are their specificity and avidity. While specificity of a mAb raised against a human protein ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/19420862.2014.985919

    authors: Liu S,Zhang H,Dai J,Hu S,Pino I,Eichinger DJ,Lyu H,Zhu H

    更新日期:2015-01-01 00:00:00

  • Rapid identification of an antibody DNA construct rearrangement sequence variant by mass spectrometry.

    abstract::During cell line development for an IgG1 antibody candidate (mAb1), a C-terminal extension was identified in 2 product candidate clones expressed in CHO-K1 cell line. The extension was initially observed as the presence of anomalous new peaks in these clones after analysis by cation exchange chromatography (CEX-HPLC) ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.36222

    authors: Scott RA,Rogers R,Balland A,Brady LJ

    更新日期:2014-01-01 00:00:00

  • Sequencing antibody repertoires: the next generation.

    abstract::Genomic studies have been revolutionized by the use of next generation sequencing (NGS) that delivers huge amounts of sequence information in a short span of time. The number of applications for NGS is rapidly expanding and significantly transforming many areas of life sciences. The field of antibody research and disc...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.3.1.14169

    authors: Fischer N

    更新日期:2011-01-01 00:00:00

  • Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.

    abstract::Therapeutic antibodies continue to develop as an emerging drug class, with a need for preclinical tools to better predict in vivo characteristics. Transgenic mice expressing human neonatal Fc receptor (hFcRn) have potential as a preclinical pharmacokinetic (PK) model to project human PK of monoclonal antibodies (mAbs)...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2016.1193660

    authors: Avery LB,Wang M,Kavosi MS,Joyce A,Kurz JC,Fan YY,Dowty ME,Zhang M,Zhang Y,Cheng A,Hua F,Jones HM,Neubert H,Polzer RJ,O'Hara DM

    更新日期:2016-08-01 00:00:00

  • Certolizumab pegol.

    abstract::Certolizumab pegol (Cimzia(®)) is currently the only PEGylated anti-TNFα biologic approved for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, is a humanized antigen-binding fragment (Fab') of a monoclonal antibody that has been conjugated to polyethylene glycol. Certolizumab pe...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.4161/mabs.2.2.11271

    authors: Goel N,Stephens S

    更新日期:2010-03-01 00:00:00

  • An accelerated surface-mediated stress assay of antibody instability for developability studies.

    abstract::High physical stability is required for the development of monoclonal antibodies (mAbs) into successful therapeutic products. Developability assays are used to predict physical stability issues such as high viscosity and poor conformational stability, but protein aggregation remains a challenging property to predict. ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1815995

    authors: Kopp MRG,Wolf Pérez AM,Zucca MV,Capasso Palmiero U,Friedrichsen B,Lorenzen N,Arosio P

    更新日期:2020-01-01 00:00:00

  • Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.

    abstract::Monoclonal antibodies play an increasingly important role for the development of new drugs across multiple therapy areas. The term 'developability' encompasses the feasibility of molecules to successfully progress from discovery to development via evaluation of their physicochemical properties. These properties includ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1743053

    authors: Bailly M,Mieczkowski C,Juan V,Metwally E,Tomazela D,Baker J,Uchida M,Kofman E,Raoufi F,Motlagh S,Yu Y,Park J,Raghava S,Welsh J,Rauscher M,Raghunathan G,Hsieh M,Chen YL,Nguyen HT,Nguyen N,Cipriano D,Fayadat-Dilma

    更新日期:2020-01-01 00:00:00

  • Non-neutralizing antibodies increase endogenous circulating Ang1 levels.

    abstract::Ang1 is a soluble ligand to receptor Tie2, and increasing the circulating Ang1 level may improve vascular stabilization under certain disease conditions. Here, we found that the circulating Ang1 level was significantly increased in cynomolgus monkeys treated with non-neutralizing anti-Ang1 antibodies. Improving the an...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1521130

    authors: Zheng C,Toth J,Bigwarfe T,MacDougall M,Jerath K,Bovat K,Smith J,Sun P,Hayes D,Fryer R,Singh S,Kroe-Barrett R

    更新日期:2018-11-01 00:00:00

  • Bridging the gap: facilities and technologies for development of early stage therapeutic mAb candidates.

    abstract::Therapeutic monoclonal antibodies (mAbs) currently dominate the biologics marketplace. Development of a new therapeutic mAb candidate is a complex, multistep process and early stages of development typically begin in an academic research environment. Recently, a number of facilities and initiatives have been launched ...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.4161/mabs.3.5.16968

    authors: Munro TP,Mahler SM,Huang EP,Chin DY,Gray PP

    更新日期:2011-09-01 00:00:00

  • Functional domain analysis of SOX18 transcription factor using a single-chain variable fragment-based approach.

    abstract::Antibodies are routinely used to study the activity of transcription factors, using various in vitro and in vivo approaches such as electrophoretic mobility shift assay, enzyme-linked immunosorbent assay, genome-wide method analysis coupled with next generation sequencing, or mass spectrometry. More recently, a new ap...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1451288

    authors: Fontaine FR,Goodall S,Prokop JW,Howard CB,Moustaqil M,Kumble S,Rasicci DT,Osborne GW,Gambin Y,Sierecki E,Jones ML,Zuegg J,Mahler S,Francois M

    更新日期:2018-05-01 00:00:00

  • Investigation of monoclonal antibody dimers in a final formulated drug by separation techniques coupled to native mass spectrometry.

    abstract::Therapeutic monoclonal antibodies (mAbs) are highly complex proteins that must be exhaustively characterized according to the regulatory authorities' recommendations. MAbs display micro-heterogeneity mainly due to their post-translational modifications, but also to their susceptibility to chemical and physical degrada...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1781743

    authors: Rouby G,Tran NT,Leblanc Y,Taverna M,Bihoreau N

    更新日期:2020-01-01 00:00:00

  • A chemical and computational approach to comprehensive glycation characterization on antibodies.

    abstract::Non-enzymatic glycation is a challenging post-translational modification to characterize due to the structural heterogeneity it generates in proteins. Glycation has become increasingly recognized as an important product quality attribute to monitor, particularly for the biotechnology sector, which produces recombinant...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1046663

    authors: Saleem RA,Affholter BR,Deng S,Campbell PC,Matthies K,Eakin CM,Wallace A

    更新日期:2015-01-01 00:00:00

  • Target-independent variable region mediated effects on antibody clearance can be FcRn independent.

    abstract::The importance of the neonatal Fc receptor (FcRn) in extending the serum half-life of monoclonal antibodies (mAbs) is well demonstrated, and has led to the development of multiple engineering approaches designed to alter Fc interactions with FcRn. Recent reports have additionally highlighted the effect of nonspecific ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2016.1208330

    authors: Kelly RL,Yu Y,Sun T,Caffry I,Lynaugh H,Brown M,Jain T,Xu Y,Wittrup KD

    更新日期:2016-10-01 00:00:00